Vivaldi Biosciences
1 known investors
Vivaldi Biosciences develops nasal-spray vaccines built on its Delta NS1 platform, a replication-deficient vaccine vector derived from a genetically modified influenza virus, for protection against epidemic and pandemic respiratory diseases. Its pipeline includes vaccines for universal influenza and Covid-19, with potential applications in infectious diseases and cancer.
Investors · 1
Frequently asked questions
- What does Vivaldi Biosciences do?
- Vivaldi Biosciences develops nasal-spray vaccines built on its Delta NS1 platform, a replication-deficient vaccine vector derived from a genetically modified influenza virus, for protection against epidemic and pandemic respiratory diseases. Its pipeline includes vaccines for universal influenza and Covid-19, with potential applications in infectious diseases and cancer.
- Who are Vivaldi Biosciences's investors?
- Vivaldi Biosciences's investors include Bay City Capital.